Scilex Holding

SCLX · NASDAQ

$2.53−$0.13 (−4.89%)TodayMarket closed · Oct 21, 4:11 AM ET

Prev close $2.66

SCLX analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Jul 17, 2025

Bull case

Scilex Holding's strategic partnerships are anticipated to provide a predictable and diversified revenue stream, which is likely to enhance its financial stability and enable further research and development initiatives. The innovative products such as SP-102 demonstrate a strong efficacy profile and safety measures, setting them apart from existing therapies, thus potentially capturing a significant market share in the non-opioid pain management sector. Additionally, the impending approval for ELYXYB® in Canada is expected to expand the company's market potential, further solidifying Scilex's position in the pain management landscape.

Bear case

Scilex Holding Co faces a negative outlook primarily due to the cautious market perception, resulting in a lower valuation that reflects broader investor sentiment sensitive to economic factors such as interest rate hikes and regulatory challenges. The company's financials are further strained by its association with Sorrento Therapeutics, which has encountered liquidity issues and market volatility, potentially undermining Scilex's efforts to establish itself independently. Additionally, the application of a 30% discount rate in valuation models emphasizes concerns regarding Scilex's clinical pipeline and product commercialization prospects, compounding the bearish sentiment surrounding the stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.